I vaguely recall a broker call from a few years ago that mentioned bronchitol for bronchiectasis was the real money spinning - bronchitol for CF was only secondary.
If you see the trials history, it is obviously that in the early days they focused more on bronchiectasis but switched over to taking CF indication to the market in 07-08 timeframe.
Another significant point is that is there currently no medication prescribed specifically for bronchiectasis suffers so its basically a greenfield with market size of 600k vs CF 80k.
In summary... huge oppurunity if data is good!
Question: if p3 trial results are bad from the outset, is it possible for the co to cancel the trial in the early days in order to save money? If this is the case, I assume that if pxs mgt took bronchiectasis trial to completion then the result must be good.
- Forums
- ASX - By Stock
- SNT
- Ann: Bronchiectasis Phase 3 Trial Milestone
Ann: Bronchiectasis Phase 3 Trial Milestone , page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
|
|||||
Last
3.3¢ |
Change
0.001(3.13%) |
Mkt cap ! $42.58M |
Open | High | Low | Value | Volume |
3.1¢ | 3.4¢ | 3.1¢ | $77.05K | 2.374M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 351201 | 3.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.4¢ | 673566 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 351201 | 0.033 |
3 | 520000 | 0.032 |
2 | 247700 | 0.031 |
4 | 1143175 | 0.030 |
7 | 1377931 | 0.029 |
Price($) | Vol. | No. |
---|---|---|
0.034 | 673566 | 1 |
0.035 | 200000 | 1 |
0.036 | 343537 | 2 |
0.039 | 16000 | 1 |
0.040 | 200565 | 2 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |